February 5, 2024
January 2, 2019
February 28, 2025
The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Alexander Wyatt discussing when we should assess biology with ctDNA. Cell free DNA (cfDNA) is from apoptosing cells shedding cfDNA into the blood, with most normal cfDNA being from the blood lineage. The average…
Read MoreFebruary 28, 2025
Harnessing Absolute ctDNA Measurements for Early Detection of Cancer Progression Recent studies indicate that measuring the absolute concentration of circulating tumor DNA (ctDNA) in patients with metastatic cancer can serve as a crucial predictive biomarker for imminent disease progression, paving the way for more timely clinical interventions. A breakthrough in metastatic cancer management has emerged…
Read MoreFebruary 26, 2025
Harnessing Absolute ctDNA Measurements for Early Detection of Cancer Progression Recent studies indicate that measuring the absolute concentration of circulating tumor DNA (ctDNA) in patients with metastatic cancer can serve as a crucial predictive biomarker for imminent disease progression, paving the way for more timely clinical interventions. A breakthrough in metastatic cancer management has emerged…
Read MoreFebruary 25, 2025
The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-line therapy. This pioneering effort was the first biomarker-driven umbrella master protocol initiated by the National Cancer Institute (NCI), the NCI’s National Clinical Trials Network led by SWOG…
Read MoreFebruary 20, 2025
On Feb. 19, crowds of former and current staffers at the Department of Health and Human Services protested outside the agency’s headquarters in Washington, D.C. As ABC News’s Hannah Demissie and Selina Wang reported on Wednesday, “Bracing the frigid temperatures, crowds of former and current federal workers protested the deep cuts to the Department of…
Read MoreFebruary 18, 2025
The nation’s health agencies were upended over the weekend by a confusing, slow-motion rollout of terminations that left staff worried about the future of various projects, including those to improve maternal health, discover new cancer treatments and provide help for 9/11 responders. Several thousand probationary employees across the Department of Health and Human Services were…
Read MoreFebruary 18, 2025
The Department of Government Efficiency has reportedly eliminated the jobs of those overseeing Elon Musk’s brain implant company Neuralink within the Food and Drug Administration, as part of President Donald Trump’s mass culling of government jobs. The firings over the weekend included about 20 employees who were part of the FDA’s office of neurological and…
Read MoreFebruary 14, 2025
A broad coalition of patient organizations today issued the following statement in response to cuts in staff, and research funding at federal agencies vital for American health. “Nearly every American family is affected by one or more of the diseases represented by our groups, and the stakes could not be higher. The United States is…
Read MoreFebruary 14, 2025
Unions representing federal government workers vowed legal action over major cuts to probationary staff across the government Friday (Feb. 13), including at HHS subagencies, though it’s still unclear precisely how many staff are affected at each subagency. The layoffs are expected to impact about 5,200 probationary employees across HHS, a source told Inside Health Policy, but…
Read MoreFebruary 11, 2025
At a recent meeting hosted by the Friends of Cancer Research, experts from industry talked through next steps for development of companion diagnostics for rare diseases, including in oncology. The ideas come as FDA’s diagnostics regulatory reforms face an uncertain future with the new administration and agency staffing changes. Introduction: FDA’s diagnostics regulatory reform and…
Read More
